Terug
Dagbereik
€ 478,03
€ 489,00
52-Weeksbereik
€ 425,00
€ 603,88
Volume
1.500.865
50D / 200D Gem.
€ 505,85
/
€ 509,44
Vorige Slotkoers
€ 477,97
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 59,4 | 0,4 |
| P/B | 9,5 | 2,9 |
| ROE % | 16,7 | 3,8 |
| Net Margin % | 28,4 | 3,9 |
| Rev Growth 5Y % | 15,2 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Hold
€ 638,75
+33.6%
Low: € 550,00
High: € 750,00
Forward K/W
47,6
Forward WPA
€ 10,05
WPA Groei (sch.)
+0,0%
Omzet Sch.
12 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 16,55
€ 15,60 – € 17,75
|
19 B | 5 |
| FY2029 |
€ 15,13
€ 14,26 – € 16,23
|
17 B | 2 |
| FY2028 |
€ 13,22
€ 12,29 – € 14,32
|
15 B | 7 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2026 |
Samath Jamie
EVP & CFO & Enterprise Technol
|
other | 28.766 | — | — |
| Jan 29, 2026 |
Leonard Keith R
Director
|
other | 369 | — | — |
| Dec 15, 2025 |
Brosius Mark
See Remarks
|
sell | 464 | € 548,49 | € 254.499 |
| Dec 12, 2025 |
Brosius Mark
See Remarks
|
sell | 312 | € 547,36 | € 170.776 |
| Dec 10, 2025 |
Curet Myriam
EVP & Chief Medical Officer
|
other | 208 | € 229,39 | — |
| Dec 10, 2025 |
Curet Myriam
EVP & Chief Medical Officer
|
sell | 104 | € 559,90 | € 58.230 |
| Nov 12, 2025 |
BARRATT CRAIG H
Director
|
other | 1.500 | € 71,32 | — |
| Nov 12, 2025 |
BARRATT CRAIG H
Director
|
sell | 750 | € 580,00 | € 435.000 |
| Nov 12, 2025 |
Leonard Keith R
Director
|
other | 1.606 | — | — |
| Sep 4, 2025 |
Ladd Amy L
Director
|
sell | 335 | € 440,69 | € 147.631 |
| Sep 3, 2025 |
Ladd Amy L
Director
|
sell | 336 | € 470,11 | € 157.957 |
| Jun 4, 2025 |
Rosa David J.
President
|
other | 851 | — | — |
| May 16, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 20 | € 563,81 | € 11.276 |
| May 15, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | € 560,00 | € 12.320 |
| May 14, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | € 563,00 | € 12.386 |
| May 13, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | € 561,67 | € 12.357 |
| May 12, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | € 551,97 | € 12.143 |
| May 1, 2025 |
Leonard Keith R
Director
|
grant | 531 | — | — |
| May 1, 2025 |
NACHTSHEIM JAMI K
Director
|
other | 4.800 | € 90,49 | — |
| May 1, 2025 |
NACHTSHEIM JAMI K
Director
|
sell | 2.400 | € 520,00 | € 1.248.000 |
Belangrijkste Punten
Revenue grew 15,22% annually over 5 years — strong growth
Earnings grew 22,97% over the past year
ROE of 16,67% — decent returns on equity
Net margin of 28,38% shows strong profitability
Debt/Equity of 0,02 — conservative balance sheet
Generating 2,49B in free cash flow
Groei
Revenue Growth (5Y)
15,22%
Revenue (1Y)20,51%
Earnings (1Y)22,97%
FCF Growth (3Y)82,28%
Kwaliteit
Return on Equity
16,67%
ROIC12,19%
Net Margin28,38%
Op. Margin29,27%
Veiligheid
Debt / Equity
0,02
Current Ratio4,87
Interest Coverage0,00
Waardering
P/E Ratio
59,44
P/B Ratio9,52
EV/EBITDA56,60
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 20,51% | Revenue Growth (3Y) | 18,86% |
| Earnings Growth (1Y) | 22,97% | Earnings Growth (3Y) | 26,03% |
| Revenue Growth (5Y) | 15,22% | Earnings Growth (5Y) | 13,77% |
| Profitability | |||
| Revenue (TTM) | 10,06B | Net Income (TTM) | 2,86B |
| ROE | 16,67% | ROA | 13,84% |
| Gross Margin | 66,00% | Operating Margin | 29,27% |
| Net Margin | 28,38% | Free Cash Flow (TTM) | 2,49B |
| ROIC | 12,19% | FCF Growth (3Y) | 82,28% |
| Safety | |||
| Debt / Equity | 0,02 | Current Ratio | 4,87 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 59,44 | P/B Ratio | 9,52 |
| P/S Ratio | 16,87 | PEG Ratio | 3,17 |
| EV/EBITDA | 56,60 | Dividend Yield | 0,00% |
| Market Cap | 169,77B | Enterprise Value | 166,70B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10,06B | 8,35B | 7,12B | 6,22B | 5,71B |
| Net Income | 2,86B | 2,32B | 1,80B | 1,32B | 1,70B |
| EPS (Diluted) | 7,87 | 6,42 | 5,03 | 3,65 | 4,66 |
| Gross Profit | 6,64B | 5,63B | 4,73B | 4,20B | 3,96B |
| Operating Income | 2,95B | 2,35B | 1,77B | 1,58B | 1,82B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 20,63B | 18,84B | 15,44B | 12,97B | 13,56B |
| Total Liabilities | 2,69B | 2,31B | 2,04B | 1,86B | 1,60B |
| Shareholders' Equity | 17,82B | 16,43B | 13,31B | 11,04B | 11,95B |
| Total Debt | 302,80M | 146,00M | 0,0 | 0,0 | 87,00M |
| Cash & Equivalents | 3,37B | 2,03B | 2,75B | 1,58B | 1,29B |
| Current Assets | 9,78B | 7,11B | 7,89B | 6,25B | 5,84B |
| Current Liabilities | 2,01B | 1,75B | 1,66B | 1,42B | 1,15B |